Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Long Beach Clinical Trials

Neither a doctor nor a teaching hospital

Research payments

$1,274,332

174 payments

Through program year 2025, Long Beach Clinical Trials is reported as receiving $1,274,332 in research payments, across 174 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $57,282 3
2024 Research $212,264 18
2023 Research $247,252 22
2022 Research $88,066 18
2020 Research $272,496 32
2019 Research $396,972 81

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $571,131 107 payments
  2. Genentech, Inc. $266,873 22 payments
  3. Sanofi Pasteur Inc. $196,927 19 payments
  4. Regeneron Pharmaceuticals, Inc. $112,205 1 payment
  5. Sanofi US Services Inc. $67,001 18 payments
  6. GlaxoSmithKline, LLC. $44,497 5 payments
  7. AstraZeneca Pharmaceuticals LP $15,697 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3 Placebocontrolled Randomized Observerblinded Study to Evaluate the Efficacy Safety and Tolerability of A Clostridium Difficile Vaccine in Adults 50 Years of Age and Older $399,983 96 payments
  2. Transmission Study Household $266,873 22 payments
  3. A Phase 2B Doubleblind Randomized Placebocontrolled Parallel Group Dose Ranging Study to Evaluate Virological Response and Safety of Oral Pf07817883 in Nonhospitalized Symptomatic Adult Participants With Covid19 $156,153 9 payments
  4. A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 $112,205 1 payment
  5. Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older $100,748 8 payments
  6. Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adults Aged 18 Years and Older $52,397 9 payments
  7. A Randomized, Double-Blind, Parallel Group, Multicenter, Stratified St $44,497 5 payments
  8. A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above $43,782 2 payments
  9. A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place $34,594 11 payments
  10. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin as Monotherapy in Patients With Type 2 Diabetes Mellitus Who Have $21,965 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record